A domestic biotech company specializing in technology to convert drugs into subcutaneous injection formulations has announced that it has received approval for sales in Japan. As the commercialization region for the anticancer drug utilizing this technology expands, there is growing interest in future sales performance. However, it is important to distinguish between the timing at which regulatory approval drives business progress and when it is reflected in the company's earnings. In the process of assessing the commercial value of the technology as well, it is advisable to verify step-by-step achievements, including overseas sales and fulfillment of contractual milestones.


In investments where business performance is confirmed step-by-step in this way, funding schedules can also be adjusted accordingly. If you are currently using margin or credit transactions, refinancing services can be leveraged to compare interest rates and repayment methods. Clarifying the source of funds for repayment and establishing your plans before deciding on the necessary scale of refinancing helps ensure clarity of purpose. Reviewing the terms of existing transactions can provide an opportunity to improve the way you manage your funds, even without committing additional investment. It is also appropriate to review product choices based on the actual repayment amount you can handle, rather than just potential returns.


HiStockLoan has maintained its No. 1 position in the industry for 22 years and provides a variety of equity financing products, including products with annual interest rates in the 5% range. The company is drawing attention as an option for investors seeking to reduce their funding burden while securing investment opportunities, not only for raising new investment capital but also for managing funds through refinancing credit and margin transactions.

Bio Platform: What Matters After Approval... Plan Repayment Schedules Together View original image

[HiStockLoan, the No. 1 in the industry: https://www.hisl.co.kr]


Meanwhile, interest in stock-backed loans continues to rise. This is because investors who do not want to miss rare investment opportunities are turning to stock-backed loans, which allow them to access additional capital for stock purchases.


One advantage of stock-backed loans is that, even if you face a forced liquidation risk due to a sharp drop in stock prices while using margin or credit, you can easily switch without providing additional collateral or selling holdings and wait for a market rebound.


◆ HiStockLoan: Industry's lowest rate in the 5% range per annum, covering not only additional investment funds but also refinancing for credit and margin transactions!

To enable all investors to experience stock-backed loans with ease, 'HiStockLoan' has launched a new securities-linked credit product available at an industry-low interest rate in the 5% range per annum. The product can be used to purchase stocks and refinance margin or credit transactions with securities firms. It is available up to four times your equity including your own capital, regardless of credit rating. In addition, investors utilizing alternative trading systems (NXT) can also take advantage of this product.


Investors interested in HiStockLoan’s tailored products can contact the customer consultation center (☎1566-5113) for expert consultation at any time, 24 hours a day, regardless of loan eligibility.


○ Launched product with industry-low interest rate in the 5% range per annum

○ ETF trading available

○ No. 1 in market share for 22 consecutive years, and recipient of the Korea First Brand Award for 17 consecutive years

○ Real-time margin/credit repayment with securities firms

○ Alternative trading system (NXT) transaction support

○ Reliable counseling quality guarantee system

* HiStockLoan Customer Center: 1566-5113

Visit now: https://www.hisl.co.kr


Seongho Electronics, Kwangjeon Electronics, Pharmicell, RFHIC, GS Engineering & Construction



※ The above content is unrelated to The Asia Business Daily’s editorial direction, and all responsibility rests with the information provider.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing